BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Oct 04, 2004
 |  BioCentury  |  Product Development

Bet on the placebo

The Phase II trial of Valentis Inc.'s Deltavasc gene therapy may have missed its endpoint in treating peripheral arterial disease (PAD), but the company thinks that all is not lost. The PINC polymer carrier portion of Deltavasc may be at least as efficacious as VLTS's angiogenic Del-1 gene and may provide an easier and cheaper route to market than the original gene therapy.

VLTS's protective interactive non-condensing (PINC) polymer technology is intended to deliver genes into cells by integrating into the cell membrane, said Chairman, President and CEO Benjamin McGraw. It has hydrophobic and hydrophilic components designed to give it the characteristics of a membrane.


Read the full 512 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >